A Study of IBI363 in Subjects with Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT06281678. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Study identification
- NCT ID
- NCT06281678
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 178 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2024 (Actual)
- Primary completion
- Mar 1, 2026 (Estimated)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Dec 19, 2024
2024 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco (UCSF) | San Francisco | California | 94143 | Recruiting |
| Ocala Oncology Center | Ocala | Florida | 34474 | Recruiting |
| BRCR Medical Center | Plantation | Florida | 33322 | Recruiting |
| University of Kansas Medical Center (KUMC) | Fairway | Kansas | 66205 | Recruiting |
| Michigan Hematology & Oncology Consultants - MedOnc Dearborn | Dearborn | Michigan | 48126 | Recruiting |
| Michigan Hematology & Oncology Consultants - MedOnc Troy | Troy | Michigan | 48098 | Recruiting |
| MD Anderson Cancer Center-University of Texas | Houston | Texas | 77025 | Recruiting |
| Oncology Consultants P.A. | Houston | Texas | 77030 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06281678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2024 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06281678 live on ClinicalTrials.gov.